Chemoradiation with adjuvant hysterectomy for stage IB-2 cervical cancer: a 10-year experience

In 2010, there were approximately 12,200 newly diagnosed cases of cervical cancer and 4,210 deaths in the USA [1]. The treatment of International Federation of Gynecology and Obstetrics stage IB-2 “bulky” cervical carcinoma continues to be debated. While survival for patients with IA and IB-1 tumors is generally reported greater than 90%, patients with stage IB-2 tumors have a worse prognosis with 5-year survivals ranging from 69% to 73% [2, 3] in case series collected prior to the use of cisplatin with primary or secondary radiation.